88 related articles for article (PubMed ID: 19642950)
1. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
Hanson BE; Vesole DH
Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
Gartner EM; Silverman P; Simon M; Flaherty L; Abrams J; Ivy P; Lorusso PM
Breast Cancer Res Treat; 2012 Feb; 131(3):933-7. PubMed ID: 22083229
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker.
Aboagye EO
Oncotarget; 2010 Jul; 1(3):163-166. PubMed ID: 21301046
[No Abstract] [Full Text] [Related]
4. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Jhaveri K; Ochiana SO; Dunphy MP; Gerecitano JF; Corben AD; Peter RI; Janjigian YY; Gomes-DaGama EM; Koren J; Modi S; Chiosis G
Expert Opin Investig Drugs; 2014 May; 23(5):611-28. PubMed ID: 24669860
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
Lodi A; Ronen SM
PLoS One; 2011; 6(10):e26155. PubMed ID: 22022547
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90: biological functions, diseases, and therapeutic targets.
Wei H; Zhang Y; Jia Y; Chen X; Niu T; Chatterjee A; He P; Hou G
MedComm (2020); 2024 Feb; 5(2):e470. PubMed ID: 38283176
[TBL] [Abstract][Full Text] [Related]
10. BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate.
Huang X; Shi D; Zou X; Wu X; Huang S; Kong L; Yang M; Xiao Y; Chen B; Chen X; Ouyang Y; Song L; Jian Y; Lin C
Theranostics; 2023; 13(1):339-354. PubMed ID: 36593950
[No Abstract] [Full Text] [Related]
11. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).
Li ZN; Luo Y
Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36367182
[TBL] [Abstract][Full Text] [Related]
12. Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy.
Jego G; Hermetet F; Girodon F; Garrido C
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861612
[TBL] [Abstract][Full Text] [Related]
13. Old and New Approaches to Target the Hsp90 Chaperone.
Sanchez J; Carter TR; Cohen MS; Blagg BSJ
Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
[TBL] [Abstract][Full Text] [Related]
14. Targeting protein quality control pathways in breast cancer.
Sannino S; Brodsky JL
BMC Biol; 2017 Nov; 15(1):109. PubMed ID: 29145850
[TBL] [Abstract][Full Text] [Related]
15. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.
Chatterjee S; Burns TF
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914774
[TBL] [Abstract][Full Text] [Related]
16. Targeting the unfolded protein response in cancer.
Ojha R; Amaravadi RK
Pharmacol Res; 2017 Jun; 120():258-266. PubMed ID: 28396092
[TBL] [Abstract][Full Text] [Related]
17. Mccrearamycins A-D, Geldanamycin-Derived Cyclopentenone Macrolactams from an Eastern Kentucky Abandoned Coal Mine Microbe.
Wang X; Zhang Y; Ponomareva LV; Qiu Q; Woodcock R; Elshahawi SI; Chen X; Zhou Z; Hatcher BE; Hower JC; Zhan CG; Parkin S; Kharel MK; Voss SR; Shaaban KA; Thorson JS
Angew Chem Int Ed Engl; 2017 Mar; 56(11):2994-2998. PubMed ID: 28140487
[TBL] [Abstract][Full Text] [Related]
18. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
Tomasini P; Walia P; Labbe C; Jao K; Leighl NB
Oncologist; 2016 Dec; 21(12):1450-1460. PubMed ID: 27807303
[TBL] [Abstract][Full Text] [Related]
19. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.
Bae J; Samur M; Munshi A; Hideshima T; Keskin D; Kimmelman A; Lee AH; Dranoff G; Anderson KC; Munshi NC
Oncoimmunology; 2014; 3(12):e970914. PubMed ID: 25941601
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic reticulum stress and cancer.
Yadav RK; Chae SW; Kim HR; Chae HJ
J Cancer Prev; 2014 Jun; 19(2):75-88. PubMed ID: 25337575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
